



PALMETTO PHARM
USE AS WRITTEN

Phone: 1-800-275-0139 • Fax: 843-972-9395

Date Shipment Needed: _____ Ship To: Patient Prescriber
 Nursing needed; Training needed ▶ All the supplies including syringes and needles will be dispensed if needed.

ASTHMA REFERRAL FORM

PATIENT INFORMATION

Patient Name: _____ DOB: _____ Sex: M F Weight: _____ lbs. kg.
SSN: _____ Phone: _____ Allergies: _____
Address: _____ City: _____ State: _____ Zip: _____
Emergency Contact: _____ Phone: _____ Please attach demographic information

PRESCRIBER INFORMATION

Prescriber: _____ NPI: _____ DEA: _____ State Lic: _____
Supervising Physician: _____ Practice Name: _____
Address: _____ City: _____ State: _____ Zip: _____
Phone: _____ Fax: _____ Key Office Contact: _____ Phone: _____

DIAGNOSIS INFORMATION / MEDICAL ASSESSMENT

J82 Pulmonary Eosinophilia J45.40 Moderate Persistent Asthma, uncomplicated J45.50 Severe Persistent Asthma, uncomplicated Other ICD10 _____
FEV1: % Pre-treatment serum IgE: <30 IU/mL ≥30-100 IU/mL >100-200 IU/mL >200-300 IU/mL >300-400 IU/mL >400-500 IU/mL >500-600 IU/mL >600-700 IU/mL
Patient's medical history includes: Positive RAST Positive skin test to perennial aeroallergen Asthma with eosinophilic phenotype Other _____
Current maintenance treatment (include dose and frequency): _____
Current exacerbation treatment (include dose and frequency): _____ Patient is a smoker or is exposed to smoke in the home: Yes No

INSURANCE INFORMATION

Please attach front and back of patient's insurance card (medical and prescription)

COPAY CARD ENROLLMENT

Please check if enrolling in copay card Copay ID: _____

PRESCRIPTION INFORMATION

Dupixent® (Dupilumab) 200 mg/1.14 mL Prefilled Syringe (2/pkg) New start Existing therapy
 Starter Dose: Inj. 400 mg (2 syringes) SQ on Day 1, then 200 mg (1 syringe) SQ every other Week starting on Day 15 QTY: 2 Refills: 0
 Starter Dose not needed.
 Maintenance Dose: Inj. 200 mg (1 syringe) SQ every 2 Weeks QTY: 1 Refills: _____
 Dupixent® (Dupilumab) 300 mg/2 mL Prefilled Syringe (2/pkg) New start Existing therapy
 Starter Dose: Inj. 600 mg (2 syringes) SQ on Day 1, then 300 mg (1 syringe) SQ every 2 Weeks starting on day 15 QTY: 2 Refills: 0
 Starter Dose not needed.
 Maintenance Dose: Inj. 300 mg (1 syringe) SQ every 2 Weeks QTY: 1 Refills: _____
 Fasenra® (Benralizumab) 30 mg/mL Prefilled Syringe (OR) Pen New start Existing therapy
 Starter Dose: Administer 30 mg SQ every 4 Weeks for 3 doses QTY: 1 box (1 pen/syringe) Refills: 2
 Starter Dose not needed.
 Maintenance Dose: Administer 30 mg SQ every 8 Weeks QTY: 1 box (1 pen/syringe) Refills: _____
 Nucala (Mepolizumab) 100 mg Vial
 100 mg SQ every 4 weeks QTY: 1 month Refills: _____
 Diluent (sterile water) 10 mL Vial – Use to reconstitute medication QTY: 1 month Refills: _____
 Syringe 18 g 1 inch (to mix) Needle 25 g (to inj.) QTY: 1 month Refills: _____
 Nucala (Mepolizumab) 100 mg/mL Autoinjector (OR) Pre-filled Syringe
 100 mg SQ every 4 weeks QTY: 1 month Refills: _____
 Xolair® (Omalizumab) 150mg Vial (OR) Pre-filled Syringe QTY: 1 month Refills: _____
 225 mg SQ every 2 weeks
 300 mg SQ every 2 weeks
 375 mg SQ every 2 weeks
 _____ mg SQ every 2 weeks
 75 mg SQ every 4 weeks (OR) 75mg Pre-filled Syringe
 150 mg SQ every 4 weeks
 225 mg SQ every 4 weeks
 300 mg SQ every 4 weeks
 375 mg SQ every 4 weeks
 _____ mg SQ every 4 weeks
 Diluent (sterile water) 10 mL Vial – Use to reconstitute medication QTY: 1 month Refills: _____
 Syringe 18 g 1 inch (to mix) Needle 25 g (to inj.) QTY: 1 month Refills: _____

I authorize Palmetto Specialty Pharm to enroll me in a manufacturer-assisted patient support program, corresponding with my prescribed therapy for purposes of receiving additional services such as, but not limited to: injection training. I further authorize the release to the corresponding manufacturer the minimum necessary information about my health condition and prescriptions to: coordinate the delivery of products and services available through the patient assistance program, aggregate de-identified data for market analysis, and provide educational information regarding therapies. I understand that I may revoke this authorization at any time in writing by sending a letter to Palmetto Specialty Pharm 1200 Two Island Ct. Suite B, Unit 100, Mt. Pleasant, SC 29466. I understand that I may refuse to sign this authorization and that my refusal will not affect my ability to obtain treatment from the pharmacy. A copy of this authorization will be utilized with the same effectiveness as the original
Patient Signature (required for participation) _____ Date _____

Prescriber's Signature: _____ DAW (Dispense as Written) Date: _____

Prescriber certifies that this referral form contains an original signature and is signed by the treating prescriber. NO STAMPED SIGNATURES WILL BE ACCEPTED. Where required by law, send electronic prescription or on official state prescription blank. In the event requested agent is not available through Palmetto Specialty Pharm, this prescription shall be forwarded to an eligible pharmacy.

IMPORTANT NOTICE: This message may contain privileged and confidential information and is intended only for the individual named. If you are not the named addressee, you should not disseminate, distribute or copy this fax. Please notify the sender immediately if you have received this document by mistake, then destroy this document. Please direct all verification or notification to Palmetto Specialty Pharm or any of its subsidiaries using the contact information provided on this coversheet.